FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223627963> ?p ?o ?g. }

• W4223627963 endingPage "45" @default.
• W4223627963 startingPage "38" @default.
• W4223627963 abstract "Alternation of osimertinib and afatinib is a potential approach to overcome osimertinib resistance and to allow complementation of drug efficacy without compromising safety in patients with epidermal growth factor receptor gene (EGFR)-mutated non-small cell lung cancer (NSCLC).Treatment-naive patients with stage IV NSCLC harboring an activating EGFR mutation (L858R or exon-19 deletion) were enrolled. Alternating cycles of osimertinib at 80 mg/day for 8 weeks followed by afatinib at 20 mg/day for 8 weeks were administered. The primary end point was 12-month progression-free survival (PFS) probability.Forty-six patients were enrolled and treated with study therapy. The 12-month PFS probability was 70.2% (60% confidence interval [CI], 63.9-75.6%; 95% CI, 54.2-81.5%), which did not meet the primary end point. After a median follow-up time of 25.7 months, the median PFS was 21.3 months (95% CI, 16.3 months-not reached). The overall response rate was 69.6% (95% CI, 54.2-82.3%). The most common treatment-related adverse events (any grade or grade ≥ 3, respectively) were diarrhea (73.9%, 4.3%), rash acneiform (63.0%, 2.2%), and paronychia (52.2%, 0%). Five cases of pneumonitis, two of grade 2 and thres of grade 3, were apparent, all of which developed during osimertinib treatment. Exploratory evaluation of circulating tumor DNA suggested that coexisting TP53 mutations did not influence PFS for the alternating therapy.Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR- mutated advanced NSCLC did not meet its primary end point, despite the encouraging efficacy and safety profile of this treatment strategy." @default.
• W4223627963 created "2022-04-15" @default.
• W4223627963 creator A5004282323 @default.
• W4223627963 creator A5010566372 @default.
• W4223627963 creator A5015271832 @default.
• W4223627963 creator A5015524135 @default.
• W4223627963 creator A5024261346 @default.
• W4223627963 creator A5025251965 @default.
• W4223627963 creator A5028588267 @default.
• W4223627963 creator A5032337115 @default.
• W4223627963 creator A5034638155 @default.
• W4223627963 creator A5037600318 @default.
• W4223627963 creator A5038101792 @default.
• W4223627963 creator A5040004004 @default.
• W4223627963 creator A5045245886 @default.
• W4223627963 creator A5049263315 @default.
• W4223627963 creator A5072916161 @default.
• W4223627963 creator A5073524299 @default.
• W4223627963 creator A5080218166 @default.
• W4223627963 creator A5081905843 @default.
• W4223627963 creator A5083024530 @default.
• W4223627963 date "2022-06-01" @default.
• W4223627963 modified "2023-09-30" @default.
• W4223627963 title "Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)" @default.
• W4223627963 cites W1546552389 @default.
• W4223627963 cites W1574226582 @default.
• W4223627963 cites W1980497534 @default.
• W4223627963 cites W1986412478 @default.
• W4223627963 cites W1999462166 @default.
• W4223627963 cites W2021341670 @default.
• W4223627963 cites W2024102664 @default.
• W4223627963 cites W2063391304 @default.
• W4223627963 cites W2088540000 @default.
• W4223627963 cites W2096198395 @default.
• W4223627963 cites W2109075732 @default.
• W4223627963 cites W2110841878 @default.
• W4223627963 cites W2111662961 @default.
• W4223627963 cites W2126709309 @default.
• W4223627963 cites W2129360604 @default.
• W4223627963 cites W2130256619 @default.
• W4223627963 cites W2132157071 @default.
• W4223627963 cites W2132540363 @default.
• W4223627963 cites W2160982674 @default.
• W4223627963 cites W2168161641 @default.
• W4223627963 cites W2337209831 @default.
• W4223627963 cites W2339311613 @default.
• W4223627963 cites W2560717039 @default.
• W4223627963 cites W2655216406 @default.
• W4223627963 cites W2747965175 @default.
• W4223627963 cites W2760639821 @default.
• W4223627963 cites W2769659311 @default.
• W4223627963 cites W2770828094 @default.
• W4223627963 cites W2775798067 @default.
• W4223627963 cites W2805414127 @default.
• W4223627963 cites W2884288428 @default.
• W4223627963 cites W2885289995 @default.
• W4223627963 cites W2903043657 @default.
• W4223627963 cites W2933725736 @default.
• W4223627963 cites W2976334328 @default.
• W4223627963 cites W2990041408 @default.
• W4223627963 cites W3016720073 @default.
• W4223627963 cites W3032247589 @default.
• W4223627963 cites W3167580159 @default.
• W4223627963 doi "https://doi.org/10.1016/j.lungcan.2022.04.004" @default.
• W4223627963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35477147" @default.
• W4223627963 hasPublicationYear "2022" @default.
• W4223627963 type Work @default.
• W4223627963 citedByCount "5" @default.
• W4223627963 countsByYear W42236279632022 @default.
• W4223627963 countsByYear W42236279632023 @default.
• W4223627963 crossrefType "journal-article" @default.
• W4223627963 hasAuthorship W4223627963A5004282323 @default.
• W4223627963 hasAuthorship W4223627963A5010566372 @default.
• W4223627963 hasAuthorship W4223627963A5015271832 @default.
• W4223627963 hasAuthorship W4223627963A5015524135 @default.
• W4223627963 hasAuthorship W4223627963A5024261346 @default.
• W4223627963 hasAuthorship W4223627963A5025251965 @default.
• W4223627963 hasAuthorship W4223627963A5028588267 @default.
• W4223627963 hasAuthorship W4223627963A5032337115 @default.
• W4223627963 hasAuthorship W4223627963A5034638155 @default.
• W4223627963 hasAuthorship W4223627963A5037600318 @default.
• W4223627963 hasAuthorship W4223627963A5038101792 @default.
• W4223627963 hasAuthorship W4223627963A5040004004 @default.
• W4223627963 hasAuthorship W4223627963A5045245886 @default.
• W4223627963 hasAuthorship W4223627963A5049263315 @default.
• W4223627963 hasAuthorship W4223627963A5072916161 @default.
• W4223627963 hasAuthorship W4223627963A5073524299 @default.
• W4223627963 hasAuthorship W4223627963A5080218166 @default.
• W4223627963 hasAuthorship W4223627963A5081905843 @default.
• W4223627963 hasAuthorship W4223627963A5083024530 @default.
• W4223627963 hasBestOaLocation W42236279631 @default.
• W4223627963 hasConcept C121608353 @default.
• W4223627963 hasConcept C126322002 @default.
• W4223627963 hasConcept C143998085 @default.
• W4223627963 hasConcept C168563851 @default.
• W4223627963 hasConcept C203092338 @default.
• W4223627963 hasConcept C2776256026 @default.
• W4223627963 hasConcept C2776694085 @default.

• next